Agreement between carotid and radial augmentation index: Does medication status affect the relation?☆

Jun Sugawara, Hidehiko Komine, Koichiro Hayashi, Mutsuko Yoshizawa, Takashi Yokoi, Seiji Maeda, Hirofumi Tanaka

To cite this article: Jun Sugawara, Hidehiko Komine, Koichiro Hayashi, Mutsuko Yoshizawa, Takashi Yokoi, Seiji Maeda, Hirofumi Tanaka (2008) Agreement between carotid and radial augmentation index: Does medication status affect the relation?☆, Artery Research 2:2, 74–76, DOI: https://doi.org/10.1016/j.artres.2008.03.001

To link to this article: https://doi.org/10.1016/j.artres.2008.03.001

Published online: 14 December 2019
Agreement between carotid and radial augmentation index: Does medication status affect the relation?

Jun Sugawara\textsuperscript{a,b,*}, Hidehiko Komine\textsuperscript{b}, Koichiro Hayashi\textsuperscript{b}, Mutsuko Yoshizawa\textsuperscript{b}, Takashi Yokoib, Seiji Maeda\textsuperscript{c}, Hirofumi Tanaka\textsuperscript{a}

\textsuperscript{a} Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, University of Texas at Austin, 1 University Station, D3700 Austin, TX 78712-1204, USA
\textsuperscript{b} Institute for Human Science and Biomedical Engineering, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan
\textsuperscript{c} Center for Advanced Research Alliance, University of Tsukuba, Ibaraki, Japan

Received 20 December 2007; received in revised form 4 March 2008; accepted 7 March 2008
Available online 28 April 2008

Summary Central augmentation index (AI) is an index for arterial stiffness and wave reflection, but the measurement requires technical precision. We recently reported that AI obtained directly from radial arterial pressure waveforms (without using the general transfer function) could provide equivalent information to carotid AI in healthy adults. The aim of the present study was to determine whether such association would exist among patients on anti-hypertensive drugs. Forty-six hypertensive patients taking blood pressure lowering medications (62 ± 9 years, mean ± SD) and 78 age-matched apparently healthy adults (60 ± 9 years) were studied. Carotid and radial AI were obtained using arterial applanation tonometry, and radial AI was calculated using the equation \[(\text{second peak radial systolic pressure - diastolic pressure})/(\text{first peak radial systolic pressure - diastolic pressure}) \times 100\]. Radial AI was strongly and positively correlated with carotid AI in medicated patients \((r = 0.73, P < 0.0001)\) as well as in healthy controls \((r = 0.84, P < 0.0001)\). The Bland–Altman plot demonstrated that the difference and SD between carotid and radial AI were not different between medicated patients and healthy controls \((61.8 ± 7.7\% vs 63.0 ± 7.7\%)\). These results suggest that radial AI may be able...
Radial and carotid augmentation index

Background

Central arterial augmentation index (AI) is a useful index of arterial wave reflection that has been directly linked with cardiovascular mortality and morbidity, but the measurement requires technical precision. We recently described a strong association between carotid AI (a surrogate for central AI) and radial AI obtained directly from pressure waveforms at both locations in healthy subjects. However, for central AI and radial AI obtained directly from pressure waveforms at both locations in healthy subjects. For central AI and radial AI obtained directly from pressure waveforms at both locations in healthy subjects.

Aim

The aim of the present study was to determine whether an association between carotid and radial AI observed in healthy adults would also exist among patients on antihypertensive drugs.

Methods

We studied 46 hypertensive patients who were taking blood pressure lowering medications (mean age: 62 ± 9 years) and 78 age-matched healthy controls (60 ± 9 years). All subjects had no apparent overt cardiovascular disease (other than hypertension) as assessed by medical history. The medicated patients used calcium channel blocker (66%), angiotensin receptor blocker (31%), α-blocker (13%), α–β-blocker (3%), angiotensin-converting enzyme inhibitor (3%), diuretics (3%), and vasodilator (i.e., nitric oxide donor, 6%). All subjects gave their written informed consent to participate. This study was reviewed and approved by the local Institutional Review Board.

All measurements were performed after an abstinence of caffeine and a 3-hour fast. After resting in supine position for at least 15 min in a quiet, temperature-controlled room, carotid and radial arterial AI were measured in a random order by two vascular testing devices equipped applanation tonometry probe incorporating an array of micropiezoresistive transducers (VP-2000, Colin Medical Technology; HEM-9010AI, Omron Healthcare) as previously reported. The characteristic points on the carotid and radial pressure waveform were assessed as previously described. Heart rate and brachial blood pressure were measured by the vascular testing device (VP-2000, Colin Medical Technology). Mann–Whitney U test was used to determine significant group differences after Kolmogorov–Smirnov and Lilliefors test for normality. Univariate correlation analysis and Bland–Altman plots were used to assess relationships between variables of interest. Forward stepwise multiple-regression analysis was performed to assess independent predictors of radial AI. The effect of the medicated status on the relation between carotid and radial AI was assessed by general linear regression model.

Results

As shown in Table 1, there were no significant differences in height, body weight, and body mass index between the two groups. As expected, systolic and diastolic blood pressures, and carotid AI, were significantly higher in medicated patients than in healthy controls. Radial AI tended to be higher in medicated patients than in healthy controls (P = 0.07). Radial AI was strongly correlated with carotid AI in medicated patients (r = 0.72, P < 0.0001, Fig. 1) as well as in healthy controls (r = 0.84, P < 0.0001, Fig. 1). The Bland–Altman plot demonstrated that the difference and SD between carotid and radial AI in medicated patients were not different from those in healthy controls (62 ± 8 vs. 63 ± 8%, P = 0.40).

In healthy controls, radial AI was significantly correlated with age (r = 0.61), sex (r = 0.59), height (r = 0.60), weight (r = 0.48), and heart rate (r = 0.40) as well as carotid AI. A forward stepwise regression analysis revealed that carotid AI (beta = 0.58), age (beta = 0.17), sex (beta = 0.16), and heart rate (beta = −0.16) were entered the model as independent predictors of radial AI (adjusted multiple R² = 0.73, P < 0.0001). Similarly, the medicated patients showed significant relationship of radial AI to heart rate (r = −0.54), age (beta = 0.33), sex (r = 0.28), and height (r = −0.23) as well as carotid AI. A forward stepwise regression analysis revealed that carotid AI (beta = 0.58) and heart rate (beta = −0.30) were entered the model as independent predictors of radial AI in the medicated patients (adjusted multiple R² = 0.59, P < 0.0001). General linear regression model revealed that radial AI was a significant independent predictor for carotid AI in the pooled subjects and that the medicated status was not entered into the model, suggesting that the medication status did

Table 1

<table>
<thead>
<tr>
<th>Physical characteristics</th>
<th>Healthy controls</th>
<th>Medicated patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>33/45</td>
<td>24/22</td>
</tr>
<tr>
<td>Age, years</td>
<td>60 ± 9</td>
<td>62 ± 9</td>
</tr>
<tr>
<td>Height, cm</td>
<td>160 ± 9</td>
<td>161 ± 8</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>59 ± 10</td>
<td>63 ± 10</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.1 ± 2.9</td>
<td>24.1 ± 2.9</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>62 ± 9</td>
<td>61 ± 7</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>121 ± 10</td>
<td>135 ± 20*</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>74 ± 8</td>
<td>82 ± 13*</td>
</tr>
<tr>
<td>Carotid AI, %</td>
<td>21.5 ± 14.0</td>
<td>27.3 ± 10.6*</td>
</tr>
<tr>
<td>Radial AI, %</td>
<td>84.5 ± 12.9</td>
<td>89.1 ± 10.3</td>
</tr>
</tbody>
</table>

Data are mean ± SD.

* P < 0.05 vs. healthy controls.

BMI = body mass index, BP = blood pressure.
Discussion

Considering the increasing emphasis placed on primary prevention of cardiovascular disease, the development of noninvasive techniques to screen high-risk patients is clearly meaningful. Our results suggest that radial AI, which is easier to measure and implement, may be able to provide qualitatively similar information to carotid AI even in patients on anti-hypertensive medications. Our findings would extend our previous findings in healthy humans \(^3\) to medicated hypertensive population.

As vasoactive agents can affect large and/or small arteries' vascular tone differentially, \(^4,5\) a question can be raised as to why a constant association between carotid and radial AI was observed regardless of the medication status. Augmentation index incorporates the magnitude as well as the timing of the incident wave from the heart and the reflected wave from the periphery. \(^6\) Since major paths of pressure wave (e.g., aorta) are common to both carotid and radial AI, acute and/or chronic influences of vasoactive agents might be expected to be similar on both carotid and radial AI. In this context, we have previously reported that acute changes in radial AI produced by sympathetic nervous activity stimulation were closely associated with the corresponding changes in carotid AI. \(^3\)

In the present study, all subjects were Japanese, and majority of them were taking calcium channel blocker and/or ARB. We recognize that the approach for treating hypertension are different among countries (i.e., Japan vs. US) \(^9,10\) and that the results might be different when similar studies are conducted in a different country. Unfortunately, our sample size was too small to analyze whether the type of drug may affect the relation between carotid and radial AI. Further study to address this issue is warranted.

Acknowledgement

The autonomic device tested for the present study was provided by the Omron Health Care Corporation, Kyoto, Japan.

References